Skip to content

The Value of Urina Sanguinis and Time-segmented Urine in Evaluating the Types of Uric Acid Excretion in Patients with Hyperuricemia

The Value of Urina Sanguinis and Time-segmented Urine in Evaluating the Types of Uric Acid Excretion in Patients with Hyperuricemia

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056813
Enrollment
Unknown
Registered
2022-02-18
Start date
2021-12-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Gold Standard:Diagnostic criteria for hyperuricemia (male and female): blood uric acid>420µmol/L
Index test:24-hour urinary uric acid excretion fraction

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old with hyperuricemia or non-hyperuricemia who were hospitalized in the Department of Endocrinology of our hospital during the study period; 2. Willing to provide demographic information such as name, gender, age, contact number, and physical measurement data such as height, weight, waist circumference, hip circumference, and blood pressure; 3. EGFR >= 60ml/min/1.73m^2 and serum creatinine < 177umol/L (2mg/ dL); 4. Patients who are willing to sign informed consent, cooperate with this study and keep relevant specimens.

Exclusion criteria

Exclusion criteria: 1. Current or previous diseases affecting uric acid metabolism (massive proteinuria, hematuria, leukemia, leukocytosis, multiple myeloma, chronic hemolytic anemia, polycythemia, myeloproliferative diseases, diabetes insipidus, malignant tumors, radiotherapy and chemotherapy, etc.); 2. Taking drugs that affect uric acid metabolism (diuretics, allopurinol, phenbromarone, sodium bicarbonate, aspirin, ethambutol, pyrazinamide, niacin, ethanol, cyclosporine, etc.) in the past one month; 3. Patients who are not willing to cooperate with the clinical study to keep urine and blood samples, with incomplete data.

Design outcomes

Primary

MeasureTime frame
blood uric acid;urate acid of urine;creatitine of blood;creatitine of urine;

Countries

China

Contacts

Public ContactLin Huandong

Zhongshan Hospital, Fudan University

lin.huandong@zs-hospital.sh.cn+86 13501887745

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026